Epitope specificity and significance in systemic autoimmune diseases

Annals of the New York Academy of Sciences

Volumn 1183, Issue , 2010, Pages 267-287

  Mahler, Michael ^a   Fritzler, Marvin J ^b  

^a Dr Fooke Laboratorien GmbH   (Germany)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Autoantibodies; Autoantigens; Autoimmunity; Epitopes; Rheumatic diseases

Indexed keywords

ANTINUCLEAR ANTIBODY; APOPTOPE; AUTOANTIBODY; AUTOANTIGEN; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CRYPTIC EPITOPE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; EPITOPE; GLUTAMATE DECARBOXYLASE; HISTIDINE TRANSFER RNA LIGASE; HISTONE ANTIBODY; JO 1 ANTIBODY; MIMOTOPE; NEOEPITOPE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NUCLEOSOME ANTIBODY; PANCREAS ISLET CELL ANTIBODY; PHOSPHOLIPID ANTIBODY; POSTTRANSLATIONALLY MODIFIED EPITOPE; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN; RIBOSOME PROTEIN; SCL 70 ANTIBODY; SYNTHETIC PEPTIDE; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; EPITOPE MAPPING; GLOMERULUS BASEMENT MEMBRANE; HUMAN; IMMUNE RESPONSE; MIXED CONNECTIVE TISSUE DISEASE; POLYMYOSITIS; REVIEW; SJOEGREN SYNDROME; SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; X RAY CRYSTALLOGRAPHY;

EID: 75749123045     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05127.x     Document Type: Review

References (127)

1. Silverstein, A.M. 2001. Autoimmunity versus horror autotoxicus: the struggle for recognition.Nat. Immunol. 2: 279-281.
2. Marrack, P., J. Kappler & B.L. Kotzin. 2001. Autoimmune disease: why and where it occurs. Nat. Med. 7: 899-905.
3. Gaubitz, M. 2006. Epidemiology of connective tissue disorders. Rheumatology (Oxford) 45(Suppl 3): iii3-iii4.
4. Helmick, C.G. et al. 2008. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58: 15-25.
5. Lawrence, R.C. et al. 2008. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58: 26-35.
6. Von Muhlen, C.A. & E.M. Tan. 1995. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin. Arthritis Rheum. 24: 323-358
7. Elkon, K.B., A.P. Parnassa & C.L. Foster. 1985. Lupus autoantibodies target ribosomal P proteins. J. Exp.Med. 162: 459-471.
8. Mahler, M. et al. 2006. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin. Vaccine Immunol. 13: 77-83.
9. Mahler, M. et al. 2008. Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res. Ther. 10: R131.
10. Walker, J.G. & M.J. Fritzler. 2007. Update on autoantibodies in systemic sclerosis. Curr. Opin. Rheumatol. 19: 580-591.
11. Schulte-Pelkum, J., M.J. Fritzler & M. Mahler. 2009. Latest update on the Ro/SS-A autoantibody system. Autoimmun. Rev. 8: 632-637.
12. Takada, K. et al. 2007. Primary biliary cirrhosis in female subjects with sicca-associated antibodies. Mod. Rheumatol. 17: 486-491.
13. Sherer, Y., A. Gorstein, M.J. Fritzler & Y. Shoenfeld. 2004. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 34: 501-537.
14. Arbuckle, M.R. et al. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349: 1526-1533.
15. Hanly, J.G., J. Robichaud & J.D. Fisk. 2006. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J. Rheumatol. 33: 1553-1558.
16. Kessenbrock, K., R. Raijmakers, M.J. Fritzler & M. Mahler. 2007. Synthetic peptides: the future of patient management in systemic rheumatic diseases? Curr. Med. Chem. 14: 2831-2838.
17. Witte, T. 2008. IgM antibodies against dsDNA in SLE. Clin. Rev. Allergy Immunol. 34: 345-347.
18. Fritzler, M.J. 2008. Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmun. Rev. 7: 616-620.
19. Routsias, J.G., P.G. Vlachoyiannopoulos & A.G. Tzioufas. 2006.Autoantibodies to intracellular autoantigens and their B-cell epitopes:molecular probes to study the autoimmune response. Crit Rev. Clin. Lab Sci. 43: 203-248.
20. Tan, E.M. 1988. Antinuclear antibodies: diagnostic markers and clues to the basis of systemic autoimmunity. Pediatr. Infect. Dis. J. 7: S3-S9.
21. Craft, J., T.Mimori, T.L.Olsen&J.A.Hardin. 1988. The U2 small nuclear ribonucleoprotein particle as an autoantigen. Analysiswith sera frompatientswith overlap syndromes. J. Clin. Invest. 81: 1716-1724.
22. Tsokos,G.C. 2006. Inthe beginning was Sm.J. Immunol. 176: 1295-1296.
23. Mahler, M., R. Mierau & M. Bluthner. 2000. Finespecificity of the anti-CENP-A B-cell autoimmune response. J. Mol. Med. 78: 460-467.
24. Mahler,M., K. Kessenbrock, J. Raats, et al. 2003. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J. Mol. Med. 81: 194-204.
25. Akbarali, Y. et al. 2006. Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies. J. Autoimmun. 27: 272-280.
26. Bluthner, M. et al. 2000. Identification of an alphahelical epitope region on the PM/Scl-100 autoantigen with structural homology to a region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides. J. Mol. Med. 78: 47-54.
27. Kessenbrock, K. et al. 2007. Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection. J. Mol. Med. 85: 953-959.
28. Aris, J.P.&G. Blobel. 1991. cDNA cloning and sequencing of human fibrillarin, a conserved nucleolar protein recognized by autoimmune antisera. Proc. Natl. Acad. Sci. USA 88: 931-935.
29. Reuter, R., G. Tessars, H.W. Vohr, et al. 1989.Mercuric chloride induces autoantibodies against U3 small nuclear ribonucleoprotein in susceptible mice. Proc. Natl. Acad. Sci. USA 86: 237-241.
30. Hultman, P., S. Enestrom, K.M. Pollard & E.M. Tan. 1989. Anti-fibrillarin autoantibodies in mercurytreated mice. Clin. Exp. Immunol. 78: 470-477.
31. Takeuchi,K., S.J.Turley, E.M.Tan&K.M. Pollard. 1995. Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity. J. Immunol. 154: 961-971.
32. Dunbar, D.A., S. Wormsley, T.M. Lowe & S.J. Baserga. 2000. Fibrillarin-associated box C/D small nucleolar RNAs in Trypanosoma brucei. Sequence conservation and implications for 2'-O-ribosemethylation of rRNA. J. Biol. Chem. 275: 14767-14776.
33. Pollard, K.M. et al. 1997. The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties. J. Immunol. 158: 3521-3528.
34. Burlingame, R.W., M.L. Boey, G. Starkebaum & R.L. Rubin. 1994. The central role of chromatin in autoimmune responses to histones andDNA in systemic lupus erythematosus. J. Clin. Invest. 94: 184-192.
35. Gomez-Puerta, J.A., R.W. Burlingame & R. Cervera. 2008. Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun. Rev. 7: 606-611.
36. Stinton, L.M. et al. 2007. Autoantibodies in lupus nephritis patients requiring renal transplantation. Lupus 16: 394-400.
37. Welin, H.E. et al. 1999. Key residues revealed in a major conformational epitope of the U1-70K protein. Proc. Natl. Acad. Sci. USA 96: 14487-14492.
38. Raats, J.M. et al. 2003. Human recombinant anti-La (SS-B) autoantibodies demonstrate the accumulation of phosphoserine-366-containing la isoforms in nucleoplasmic speckles. Eur. J. Cell Biol. 82: 131-141.
39. Hof,D. et al. 2005.Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease. Arthritis Res. Ther. 7: R302-R309.
40. Hof,D., J.M. Raats & G.J. Pruijn. 2005. Apoptoticmodifications affect the autoreactivity of the U1 snRNP autoantigen. Autoimmun. Rev. 4: 380-388.
41. Eggleton, P., R. Haigh & P.G. Winyard. 2008. Consequence of neo-antigenicity of the 'altered self'. Rheumatology (Oxford) 47: 567-571.
42. Kurien, B.T. & R.H. Scofield. 2008. Autoimmunity and oxidatively modified autoantigens. Autoimmun. Rev. 7: 567-573.
43. Doyle, H.A. & M.J. Mamula. 2005. Posttranslational modifications of self-antigens. Ann. N. Y. Acad. Sci. 1050: 1-9.
44. Elsaid, K.A. & C.O. Chichester. 2006. Review: Collagen markers in early arthritic diseases. Clin.Chim.Acta 365: 68-77.
45. Chen,H.C. et al. 2008. Biomarkers associatedwith clinical phenotypes of hand osteoarthritis in a large multigenerational family: the CARRIAGE family study. Osteoarthritis. Cartilage 16: 1054-1059.
46. Mahler, M., R. Mierau, W. Schlumberger & M. Bluthner. 2001. A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1. J. Mol. Med. 79: 722-731.
47. Clemens, M.J., W.J. Van Venrooij & L.B. Van De Putte. 2000. Apoptosis and autoimmunity. Cell Death. Differ. 7: 131-133.
48. Reed, J.H. et al. 2007. Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes. Clin. Exp. Immunol. 148: 153-160.
49. Reed, J.H., M.W. Jackson & T.P. Gordon. 2008. B cell apotopes of the 60-kDa Ro/SSA and La/SSB autoantigens. J. Autoimmun. 31: 263-267.
50. Lleo, A. et al. 2009. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology 49: 871-879.
51. Degraaf, M.E., R.M. Miceli, J.E. Mott & H.D. Fischer. 1993. Biochemical diversity in a phage display library of random decapeptides. Gene 128: 13-17.
52. Putterman, C. & B. Diamond. 1998. Immunization with a peptide surrogate for double-strandedDNA (ds- DNA) induces autoantibody production and renal immunoglobulin deposition. J. Exp. Med. 188: 29-38.
53. Sun, Y., K.Y. Fong, M.C. Chung & Z.J. Yao. 2001. Peptide mimicking antigenic and immunogenic epitope of double-stranded DNA in systemic lupus erythematosus. Int. Immunol. 13: 223-232.
54. Zhang, W. & M. Reichlin. 2005. A peptide DNA surrogate that binds and inhibits anti-dsDNA antibodies. Clin. Immunol. 117: 214-220.
55. Thomas, J.O., C.M. Wilson & J.A. Hardin. 1984. The major core histone antigenic determinants in systemic lupus erythematosus are in the trypsin-sensitive regions. FEBS Lett. 169: 90-96.
56. Gohill, J., P.D. Cary, M. Couppez & M.J. Fritzler. 1985. Antibodies from patients with drug-induced and idiopathic lupus erythematosus react with epitopes restricted to the amino and carboxyl termini of histone. J. Immunol. 135: 3116-3121.
57. Pauls, J.D., J. Gohill & M.J. Fritzler. 1990. Antibodies from patients with systemic lupus erythematosus and drug-induced lupus bind determinants on histone 5 (H5). Mol. Immunol. 27: 701-711.
58. Mahler, M., M. Bluthner & K.M. Pollard. 2003. Advances in B-cell epitope analysis of autoantigens in connective tissue diseases. Clin. Immunol. 107: 65-79.
59. Farrag, L. et al. 2007. A study of conformational restraints on reactivity of human PR3-specific autoantibodies (ANCA) facilitated through protein folding manipulations of a new recombinant proteinase 3 protein. Autoimmunity 40: 503-511.
60. Ben Yehezkel, T. et al. 2008. De novo DNA synthesis using single molecule PCR. Nucleic Acids Res. 36: e107.
61. Gershoni, J.M. et al. 2007. Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs 21: 145-156.
62. Rowley,M.J., K. O'Connor&L.Wijeyewickrema. 2004. Phage display for epitope determination: a paradigm for identifying receptor-ligand interactions. Biotechnol. Annu. Rev. 10: 151-188.
63. Smith, G.P. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228: 1315-1317.
64. Westerlund-Wikstrom, B. 2000. Peptide display on bacterial flagella: principles and applications. Int. J. Med. Microbiol. 290: 223-230.
65. Bluthner, M. & F.A. Bautz. 1992. Cloning and characterization of the cDNA coding for a polymyositisscleroderma overlap syndrome-related nucleolar 100- kD protein. J. Exp. Med. 176: 973-980.
66. Bluthner, M., E.K. Bautz & F.A. Bautz. 1996. Mapping of epitopes recognized by PM/Scl autoantibodies with gene-fragment phage display libraries. J. Immunol. Methods 198: 187-198.
67. Bluthner, M., C. Schafer, C. Schneider & F.A. Bautz. 1999. Identification of major linear epitopes on the sp100 nuclear PBC autoantigen by the gene-fragment phage-display technology. Autoimmunity 29: 33-42.
68. Frank, R. 2002. The SPOT-synthesis technique. Synthetic peptide arrays onmembrane supports-principles and applications. J. Immunol. Methods 267: 13-26.
69. Reineke, U. et al. 2002. Identification of distinct antibody epitopes and mimotopes from a peptide array of 5520 randomly generated sequences. J. Immunol.Methods 267: 37-51.
70. Frank, R. & J. Schneider-Mergener. 2002. SPOT synthesis-scope of applications. In Peptides Arrays on Membrane Supports - Synthesis and Applications, Vol.1. Koch, J. & M. Mahler, Eds.: 1-22. Springer. Berlin, Heidelberg, New York.
71. Zander, N. & H. Gausepohl. 2002. Chemistry of Fmoc peptide synthesis on membranes. In Peptides Arrays on Membrane Supports - Synthesis and Applications, Vol.1. Koch, J. & M. Mahler, Eds.: 23-39. Springer. Berlin, Heidelberg, New York.
72. Riemekasten, G. et al. 1998. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J. Clin. Invest. 102: 754-763.
73. Eystathioy, T. et al. 2003. A panel of monoclonal antibodies to cytoplasmicGWbodies and the mRNA binding protein GW182. Hybrid. Hybridomics 22: 79-86.
74. Eystathioy, T. et al. 2003. Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. J.Mol.Med. 81: 811-818.
75. Mahler, M. et al. 2005. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res. Ther. 7: R704-R713.
76. Mahler, M., M.J. Fritzler & M. Bluthner. 2005. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res. Ther. 7: R19-R29.
77. Groves, M. & I. Sinning. 2002. Protein-protein interactions. In Peptides Arrays on Membrane Supports - Synthesis and Applications. Koch, J. & M. Mahler, Eds.: 83-96. Springer. Berlin, Heidelberg, New York.
78. Reuter, M. & E. Möncke-Buchner. 2002. Analysis of protein-DNA interactions. In Peptides Arrays on Membrane Supports - Synthesis and Applications, Vol.1. Koch, J. & M. Mahler, Eds.: 97-107. Springer. Berlin, Heidelberg, New York.
79. Mahler, M., M. Bluthner & J. Koch. 2002. Affinity purification and competition assays using solid-phase oligopeptides. In Peptides Arrays on Membrane Supports - Synthesis and Applications, Vol.1. Koch, J.&M. Mahler, Eds.: 107-122. Springer. Berlin, Heidelberg, New York.
80. Geysen,H.M. et al. 1987. Strategies for epitope analysis using peptide synthesis. J. Immunol.Methods 102: 259-274.
81. Ede, N.J. 2002.Multiple parallel synthesis of peptides on SynPhase grafted supports. J. Immunol. Methods 267: 3-11.
82. Pauls, J.D., S.M. Edworthy & M.J. Fritzler. 1993. Epitope mapping of histone 5 (H5) with systemic lupus erythematosus, procainamide-induced lupus and hydralazine-induced lupus sera. Mol. Immunol. 30: 709-719.
83. James, J.A.&J.B.Harley. 1995. Peptide autoantigenicity of the small nuclear ribonucleoprotein C. Clin. Exp. Rheumatol. 13: 299-305.
84. Migliorini, P., C. Baldini, V. Rocchi & S. Bombardieri. 2005. Anti-Sm and anti-RNP antibodies. Autoimmunity 38: 47-54.
85. Poole, B.D. et al. 2009. Early targets of nuclear RNP humoral autoimmunity in human systemic lupus erythematosus. Arthritis Rheum. 60: 848-859.
86. Houghten, R.A. et al. 1991. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 354: 84-86.
87. Lam, K.S. et al. 1991. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354: 82-84.
88. Duquerroy, S. et al. 2007. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. J. Mol. Biol. 368: 1321-1331.
89. Arbuckle, M.R., M. Reichlin, J.B. Harley & J.A. James. 1999. Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. Scand. J. Immunol. 50: 447-455.
90. James, J.A. & J.B.Harley. 1998. B-cell epitope spreading in autoimmunity. Immunol. Rev. 164: 185-200.
91. Mahler, M., R. Mierau, E. Genth & M. Bluthner. 2002. Development of a CENP-A/CENP-B-specific immune response in a patient with systemic sclerosis. Arthritis Rheum. 46: 1866-1872.
92. Deshmukh, U.S. et al. 2005. Epitope spreading within lupus-associated ribonucleoprotein antigens. Clin. Immunol. 117: 112-120.
93. McClain, M.T. et al. 2005. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat. Med. 11: 85-89.
94. Poole, B.D., R.H. Scofield, J.B. Harley & J.A. James. 2006. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39: 63-70.
95. McClain,M.T. et al. 2006. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum. 54: 360-368.
96. Brahms, H. et al. 2000. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Smautoantibodies. J. Biol. Chem. 275: 17122-17129.
97. Van Venrooij,W.J. & G.J. Pruijn. 2000. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res. 2: 249-251.
98. Zhou, Z. & H.A. Menard. 2002. Autoantigenic posttranslationalmodifications of proteins: does it apply to rheumatoid arthritis? Curr. Opin. Rheumatol. 14: 250-253.
99. Miranda, T.B. et al. 2004. Spliceosome Smproteins D1, D3, and B/B' are asymmetrically dimethylated at arginine residues in the nucleus. Biochem. Biophys. Res. Commun. 323: 382-387.
100. Kiani, A.N., J.A.Mahoney &M. Petri. 2007. Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. J. Rheumatol. 34: 1502-1505.
101. Mahler, M., L.M. Stinton & M.J. Fritzler. 2005. Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay. Clin. Diagn. Lab Immunol. 12: 107-113.
102. Fritzler,M.J. et al. 2003. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J. Rheumatol. 30: 2374-2381.
103. Gabrielli, A., S. Svegliati, G. Moroncini & E.V. Avvedimento. 2007. Pathogenic autoantibodies in systemic sclerosis. Curr. Opin. Immunol. 19: 640-645.
104. Muller, S., J. Dieker, A. Tincani & P.L. Meroni. 2008. Pathogenic anti-nucleosome antibodies. Lupus 17: 431-436.
105. Looney, R.J., J. Anolik & I. Sanz. 2004. B cells as therapeutic targets for rheumatic diseases. Curr. Opin. Rheumatol. 16: 180-185.
106. Tieng, A.T.&E.Peeva. 2008. B-cell-directed therapies in systemic lupus erythematosus. Semin. Arthritis Rheum. 38: 218-227.
107. Iikuni, N., B.H. Hahn & A. La Cava. 2009. Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus. Expert. Opin. Biol. Ther. 9: 201-206.
108. La Cava, A. 2009. Lupus and T cells. Lupus 18: 196-201.
109. Van Venrooij, W.J., J.J. Van Beers & G.J. Pruijn. 2008. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1143: 268-285.
110. Santiago, M. et al. 2008. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin. Rheumatol. 27: 77-83.
111. Vander, C.B. et al. 2008. Do all anti-citrullinated protein/ peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/ peptide antibody tests in patientswith andwithout rheumatoid arthritis. Ann. Rheum. Dis. 67: 542-546.
112. Dos Anjos, L.M. et al. 2009. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin. Rheumatol. 28: 153-158.
113. Mathsson, L. et al. 2008. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 58: 36-45.
114. Mutlu, N. et al. 2009. Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis. J. Rheumatol. 36: 491-500.
115. Seyversen, S.W. et al. 2009. Antibodies againstmutated citrullinated vimentin are better predictors of radiographic progression than antibodies against clycic citrullinated peptides. Ann. Rheum. Dis. 68: A1-A56.
116. Mahler, M., R. Raijmakers & M.J. Fritzler. 2007. Challenges and controversies in autoantibodies associated with systemic rheumatic diseases.Curr.Rheumatol.Rev. 3: 67-78.
117. Fritzler, M.J., J. Ngo, H. Hou & M. Mahler. 2008. Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. 10th International Workshop on Autoantibodies and Autoimmunity (Poster), Guadalajara, Mexico.
118. Ahmed, M.M. et al. 2006. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am. J. Med. Sci. 331: 252-256.
119. Tan, E.M. & H.G. Kunkel. 1966. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J. Immunol. 96: 464-471.
120. Tan, E.M. et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271-1277.
121. Rokeach, L.A.,M. Jannatipour & S.O.Hoch. 1990.Heterologous expression and epitope mapping of a human small nuclear ribonucleoprotein-associated Sm- B'/B autoantigen. J. Immunol. 144: 1015-1022.
122. Dieker, J.W. et al. 2006. The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by double-stranded DNA and nucleosomes. Ann. Rheum. Dis. 65: 1525-1528.
123. Mahler, M., A. Waka, F. Hiepe & M.J. Fritzler. 2007. Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus. Arthritis Res. Ther. 9: R68.
124. Mahler, M. & R. Raijmakers. 2007. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun. Rev. 6: 432-437.
125. Hanke, K. et al. 2009. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res. Ther. 11: R22.
126. Mahler, M. & M.J. Fritzler. 2009. The changing landscape of the clinical value of the PM/Scl autoantibody system. Arthritis Res. Ther. 11: 106.
127. Schett, G. et al. 2008. B-cell epitopes of the heterogeneous nuclear ribonucleoprotein A2: Identification of a new specific antibody marker for active lupus disease. Ann. Rheum. Dis. 69: 729-735.